D3.346 - Impact of local craniocerebral hypothermia on inflammatory cytokine production in ischemic stroke

Poster abstract

Background

Multiple pathophysiologic changes after ischemic stroke induce  neuroinflammation, abnormal activation of immune cells, and neuronal death. Inflammatory responses due to  increased production of proinflammatory cytokines, chemokines and adhesion molecules are key factors of ischemic tissue damage including  progression of ischemic stroke. Therapeutic approaches to reduce the activity of inflammatory cytokines may become  key to suppressing inflammatory processes that occur during ischemic stroke. Local craniocerebral hypothermia (LCCH) may suppress inflammation  in patients with acute cerebrovascular disorders. This study investigates the impact of LCСH on the production of  inflammatory cytokines.  

Method

The study included 18 patients with acute cerebrovascular accident consistent with the diagnosis of ischemic stroke. The main group included 16 patients who underwent LCCH sessions along with standard basic therapy. The control group (n=20) received only the standard basic therapy. Pro-inflammatory cytokines (IL-6, TNFa and IL-1a) in blood plasma of patients  were assessed by ELISA using test KITs (RayBiotech, USA) on the immune analyzer ANTHOS 2010 (Anthos Labtec Instruments GmbH, Austria).

Results

The investigation demonstrated an increase in all studied cytokines compared to reference values in ischemic stroke patients.  IL-6 showed a more pronounced increase (23.12+ 2.41 ng/ml) than other cytokines. The concentrations of Il-1a was 12.10 ± 3.18 ng/ml and TNFa was 7.54 ± 2.45  ng/ml, respectively. After LCCH sessions along with standard basic therapy there was a  decrease in  the concentration of the studied pro-inflammatory cytokines by 2.3 fold for IL-6; 1.68 fold for Il-1a;  and 1.76 fold for  TNFa, respectively. There was a less pronounced (p=0.05)  decrease in all the cytokines of the control group treated with standard therapy without LCCH.

Conclusion

LCCH  therapy added to standard basic therapy for ischemic stroke may  induce a more pronounced  decrease in the concentration of  major proinflammatory cytokines compared to the effect of standard basic therapy for ischemic stroke.